Form 4: Health Catalyst COO Daniel LeSueur Sells Shares Under 10b5-1 Trading Plan

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,208 shares of common stock at a price of $6.1538 per share on July 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 3, 2024, Daniel LeSueur, the Chief Operating Officer of Health Catalyst, Inc. (HCAT), sold 5,208 shares of the company's common stock.
• The sale was executed at a price of $6.1538 per share.
• This transaction was conducted under a pre-arranged written trading plan adopted on March 7, 2024, in accordance with Rule 10b5-1.
• Following the transaction, LeSueur directly owns 155,215 shares of Health Catalyst common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the executive's outlook on the company. It's a routine transaction.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on material non-public information. The market typically views these sales in the context of the overall health and prospects of the company.

Stakeholder Impact

• The sale of shares by a high-ranking officer could create uncertainty among shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates